“The unique nature of BA3071 provides an exciting opportunity to combine this CTLA-4 antibody with our anti-PD-1 antibody, tislelizumab. We look forward to working with BioAtla through proof-of-concept, followed by global development of this potentially unique cancer therapy as a single agent or in combination with other therapies,” Wang added.
Under the terms of the agreement, BioAtla will co-develop BA3071 to meet predefined goals, while BeiGene will be responsible for leading the development and commercialization of the product candidate, as well as for filing global regulatory documentation.
BeiGene will co-own an exclusive license with BioAtla to develop and produce the product candidate worldwide, as well as hold an exclusive license to commercialize the product on a global scale.
BeiGene will provide financial support to cover development, manufacturing and commercialization costs of the product candidate in Asia, Australia, and New Zealand, and will share all costs, commercial profits, and losses with BioAtla in other parts of the world.
“We believe that our collaboration with BeiGene will accelerate the global development and potential commercialization of BA3071 and advance the prospects and potential of safer and more effective combination therapies for the treatment of several cancer indications,” said Jay M. Short, PhD, chairman, CEO, and co-founder of BioAtla.
“The application of BioAtla’s CAB technology to CTLA-4 inhibition may offer greater potency and safety, thereby improving this important cancer therapy and expanding its potential applications.”
BioAtla is planning to file an investigational new drug application for BA3071 to the U.S. Food and Drug Administration later this year.